Glucokinase activators as potential antidiabetic agents possessing superior glucose-lowering efficacy

Drugs of the Future

Volumn 34, Issue 8, 2009, Pages 641-653

  Fyfe, M C T ^a   Procter, M J ^a  

^a (OSI) Prosidion   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOHEXYL 1 (4 METHANESULFONYLPHENYL)CYCLOPROPANECARBOXYLIC ACID 2 THIAZOLYLAMIDE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; ARRY 403; ARRY 588; AZD 1656; AZD 6370; C PEPTIDE; ENZYME ACTIVATOR; GKA 1; GKA 2; GKA 22; GKA 50; GKA 71; GLIMEPIRIDE; GLIPIZIDE; GLUCOKINASE; GLUCOKINASE ACTIVATOR; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; METFORMIN; MK 0599; PIOGLITAZONE; PIRAGLIATIN; PSN 010; PSN 105; PSN GK 1; R 1440; RO 28 1675; RO 4389620; SITAGLIPTIN; TTP 355; TTP 399; TTTP 399; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; CALCIUM CELL LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME STRUCTURE; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; GLYCOLYSIS; HEADACHE; HIGH THROUGHPUT SCREENING; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; KILLER CELL; L CELL; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; REVIEW;

EID: 84930540987     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.08.1394557     Document Type: Review

References (109)

1. Wild, S., Roglic, G., Green, A., Sicree, R., King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5): 1047-53.
2. Zimmet, P., Alberti, K.G.M.M., Shaw, J. Global and societal implications of the diabetes epidemic. Nature 2001, 414(6865): 782-7.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131): 837-53.
4. Fox, C.S., Coady, S., Sorlie, P.D. et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation 2007, 115(12): 1544-50.
5. Ramlo-Halsted, B.A., Edelman, S.V. The natural history of type 2 diabetes: Implications for clinical practice. Primary Care 1999, 26(4): 771-89.
6. Gershell, L. Type 2 diabetes market. Nat Rev Drug Discov 2005, 4(5): 367-8.
7. Kimmel, B., Inzucchi, S.E. Oral agents for type 2 diabetes: An update. Clin Diabet 2005, 23(2): 64-76.
8. Cefalu, W.T., Waldman, S., Ryder, S. Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: Rationale and specific agents. Clin Pharmacol Ther 2007, 81(5): 636-49.
9. Nathan, D.M. Finding new treatments for diabetes - How many, how fast... How good? New Engl J Med 2007, 356(5): 437-40.
10. Magnuson, M.A., Matschinsky, F.M. Glucokinase as a glucose sensor: Past, present, and future. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. F.M. Matschinsky, M.A. Magnuson (Eds.). Karger: Basel, 2004, 1-17.
11. Matschinsky, F.M., Magnuson, M.A., Zelent, D., Jetton, T.L., Doliba, N., Han, Y., Taub, R., Grimsby, J. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006, 55(1): 1-12.
12. Theodorakis, M.J., Carlson, O., Michopoulos, S., Doyle, M.E., Juhaszova, M., Petraki, K., Egan, J.M. Human duodenal enteroendocrine cells: Source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006, 290(3): E550-9.
13. Kang, L., Dunn-Meynell, A.A., Routh, V.H. et al. Glucokinase is a critical regulator of ventromedial hypothalamic neuronal glucosensing. Diabetes 2006, 55(2): 412-20.
14. Sorenson, R.L., Stout, L.E., Brelje, T.C., Jetton, T., Matschinsky, F.M. Immunohistochemical evidence for the presence of glucokinase in the gonadotropes and thyrotropes of the anterior pituitary gland of rat and monkey. J Histochem Cytochem 2007, 55(6): 555-66.
15. Matschinsky, F.M., Glaser, B., Magnuson, M.A. Pancreatic β-cell glucokinase: Closing the gap between theoretical concepts and experimental realities. Diabetes 1998, 47(3): 307-15.
16. Agius, L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008, 414(1): 1-18.
17. van Schaft ingen, E., Veiga da Cunha, M. Discovery and role of glucokinase regulatory protein. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. F.M. Matschinsky, M.A. Magnuson (Eds.). Karger: Basel, 2004, 193-207.
18. Cárdenas, M.L., Cornish-Bowden, A., Ureta, T. Evolution and regulatory role of the hexokinases. Biochim Biophys Acta 1998, 1401(3): 242-64.
19. Christesen, H.B.T., Herold, K., Noordam, K., Gloyn, A.L. Glucokinase-linked hypoglycaemia: Clinical aspects of activating glucokinase mutations. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. F.M. Matschinsky, M.A. Magnuson (Eds.). Karger: Basel, 2004, 75-91.
20. Christesen, H.B.T., Brusgaard, K., Nielsen, H.B., Jacobsen, B.B. Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: Hypoglycaemia unawareness and attacks. Clin Endocrinol 2008, 68(5): 747-55.
21. Velho, G., Froguel, P., Gloyn, A., Hattersley, A. Maturity onset diabetes of the young type 2. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. F.M. Matschinsky, M.A. Magnuson (Eds.). Karger: Basel, 2004, 42-64.
22. Njolstad, P.R., Sovik, O., Matschinsky, F.M., Bell, G.I. Permanent neonatal diabetes mellitus due to glucokinase deficiency. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. F.M. Matschinsky, M.A. Magnuson (Eds.). Karger: Basel, 2004, 65-74.
23. Caro, J.F., Triester, S., Patel, V.K., Tapscott, E.B., Frazier, N.L., Dohm, G.L. Liver glucokinase: Decreased activity in patients with type II diabetes. Horm Metab Res 1995, 27(1): 19-22.
24. Del Guerra, S., Lupi, R., Marselli, L. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005, 54(3): 727-35.
25. Printz, R.L., Granner, D.K. Tweaking the glucose sensor: Adjusting glucokinase activity with activator compounds. Endocrinology 2005, 146(9): 3693-5.
26. Johnson, T.O., Humphries, P.S. Glucokinase activators for the treatment of type 2 diabetes. Annu Rep Med Chem 2006, 41: 141-54.
27. Guertin, K.R., Grimsby, J. Small molecule glucokinase activators as glucose lowering agents: A new paradigm for diabetes therapy. Curr Med Chem 2006, 13(15): 1839-43.
28. Sarabu, R., Berthel, S.J., Kester, R.F., Tilley, J.W. Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin Ther Patents 2008, 18(7): 759-68.
29. Grimsby, J., Berthel, S.J., Sarabu, R. Glucokinase activators for the potential treatment of type 2 diabetes. Curr Top Med Chem 2008, 8(17): 1524-32.
30. Coghlan, M., Leighton, B. Glucokinase activators in diabetes management. Expert Opin Investig Drugs 2008, 17(2): 145-67.
31. Matschinsky, F.M. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009, 8(5): 399-416.
32. Moses, R., Slobodniuk, R., Boyages, S. et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999, 22(1): 119-24.
33. Van Gaal, L.F., De Leeuw, I.H. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003, 46(Suppl. 1): M44-50.
34. Brocklehurst, K.J., Payne, V.A., Davies, R.A. et al. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 2004, 53(3): 535-41.
35. Sarabu, R., Grimsby, J. Targeting glucokinase activation for the treatment of type 2 diabetes - A status review. Curr Opin Drug Discov Devel 2005, 8(5): 631-7.
36. Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 2004, 1(4): 337-41.
37. Ralph, E.C., Thomson, J., Almaden, J., Sun, S. Glucose modulation of glucokinase activation by small molecules. Biochemistry 2008, 47(17): 5028-36.
38. Grimsby, J., Matschinsky, F.M., Grippo, J.F. Discovery and actions of glucokinase activators. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. F.M. Matschinsky, M.A. Magnuson (Eds.). Karger: Basel, 2004, 360-78.
39. Dunten, P., Swain, A., Kammlott, U. et al. Crystal structure of human liver glucokinase bound to a small molecule allosteric activator. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. F.M. Matschinsky, M.A. Magnuson (Eds.). Karger: Basel, 2004, 145-54.
40. Kamata, K., Mitsuya, M., Nishimura, T., Eiki, J., Nagata, Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 2004, 12(3): 429-38.
41. Efanov, A.M., Barrett, D.G., Brenner, M.B. et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 2005, 146(9): 3696-701.
42. Kumari, V., Li, C. Comparative docking assessment of glucokinase interactions with its allosteric activators. Curr Chem Genom 2008, 2: 76-89.
43. Nishimura, T., Iino, T., Mitsuya, M. et al. Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators. Bioorg Med Chem Lett 2009, 19(5): 1357-60.
44. Mitsuya, M., Kamata, K., Bamba, M. et al. Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators. Bioorg Med Chem Lett 2009, 19(10): 2718-21.
45. Zelent, B., Odili, S., Buettger, C. et al. Sugar binding to recombinant wildtype and mutant glucokinase monitored by kinetic measurement and tryp-tophan fluorescence. Biochem J 2008, 413(2): 269-80.
46. Harrison, C. Patent watch - Glucokinase activators. Nat Rev Drug Discov 2009, 8(5): 350-1.
47. Grimsby, J., Sarabu, R., Corbett, W.L. et al. Allosteric activators of glucokinase: Potential role in diabetes therapy. Science 2003, 301(5631): 370-3.
48. Tannu, S., Ping, L., Spence, C. et al. A novel glucokinase activator increases hepatic glycogen synthesis and insulin sensitivity in the conscious rat. Diabetes 2001, 50(Suppl. 2): 1251-P.
49. Grimsby, J. Antidiabetic effects of glucokinase activators: From bench to bedside. Keystone Symp Diabetes Mellitus Insulin Action Resist (Jan 22-27, Breckenridge) 2008, Abst 151.
50. Kester, R.F., Sarabu, R., Corbett, W.L. et al. Discovery of an allosteric activator of glucokinase. 237th ACS Natl Meet (March 22-26, Salt Lake City) 2009, MED1 162.
51. Corbett, W.L. Glucokinase activators: Discovery of novel, orally active glucose lowering agents. Mol Med Tri-Conf Master Med Chem (March 23-26, San Francisco) 2004.
52. Kester, R.F., Corbett, W.L., Sarabu, R. et al. Discovery of piragliatin, a small molecule activator of GK. 238th ACS Natl Meet (Aug 16-20, Washington, D.C.) 2009, MEDI 5.
53. Zhai, S., Mulligan, M.-E., Grimsby, J., Arbet-Engels, C., Boldrin, M., Balena, R., Zhi, J. Phase I assessment of a novel glucokinase activator RO4389620 in healthy male volunteers. Diabetologia 2008, 51(Suppl. 1): Abst 928.
54. Bonnadonna, R.C., Kapitza, C., Heise, T. et al. Glucokinase activator RO4389620 improves plasma glucose concentrations, beta-cell function, endogenous glucose output and glucose utilization in patients with type 2 diabetes. Diabetes 2008, 57(Suppl. 1): 332-OR.
55. Bonnadonna, R.C., Kapitza, C., Heise, T. et al. Glucokinase activator RO4389620 improves beta cell function and plasma glucose fluxes in patients with type 2 diabetes. Diabetologia 2008, 51(Suppl. 1): Abst 927.
56. Zhi, J., Zhai, S., Mulligan, M.-E., Grimsby, J., Arbet-Engels, C., Boldrin, M., Balena, R. A novel glucokinase activator RO4389620 improved fasting and postprandial plasma glucose in type 2 diabetic patients. Diabetologia 2008, 51(Suppl. 1): Abst 42.
57. Pfefferkorn, J.A., Lou, J., Minich, M.L. et al. Pyridones as glucokinase activators: Identification of a unique liability of the 4-sulfonyl-2-pyridone heterocycle. Bioorg Med Chem Lett 2009, 19(12): 3247-52.
58. Leighton, B., Atkinson, A., Coghlan, M.P. Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 2005, 33(Pt. 2): 371-4.
59. McKerrecher, D., Allen, J.V., Bowker, S.S. et al. Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorg Med Chem Lett 2005, 15(8): 2103-6.
60. McKerrecher, D., Allen, J.V., Caulkett, P.W.R. et al. Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg Med Chem Lett 2006, 16(10): 2705-9.
61. Coope, G.J., Atkinson, A.M., Allott, C et al. Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 2006, 149(3): 328-35.
62. Johnson, D., Shepherd, R.M., Gill, D., Gorman, T., Smith, D.M., Dunne, M.J. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes 2007, 56(6): 1694-702.
63. Johnson, D., Shepherd, R.M., Gill, D., Gorman, T., Smith, D.M., Dunne, M.J. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes 2007, 56(Suppl. 1): 592-P.
64. Fradet, M., Giroix, M.-H., Bailbe, D., El Bawab, S., Autier, V., Kergoat, M., Portha, B. Glucokinase activators modulate glucose metabolism and glucose-induced insulin secretion in islets from GK/Par rats. Diabetologia 2008, 51(Suppl. 1): Abst 481.
65. Mullooly, N., Newsholme, P., Smith, D. Assessment of the AstraZeneca glucokinase activator GKA50 on pancreatic beta cell function and viability in the clonal beta cell line BRIN-BD11. Diabetologia 2008, 51(Suppl. 1): Abst 488.
66. Coghlan, M. Glucokinase activators in diabetes management: The discovery and pre-clinical evaluation of glucokinase activators (GKAs). Obesity Drug Dev World (Nov 26-28, London) 2007.
67. Gill, D., Smith, D.M. Upregulation of key β cell genes and improvement of function in rodent islets following chronic in vitro treatment with a glucokinase activator. Diabetologia 2007, 50(Suppl. 1): Abst 519.
68. de Koning, E.J.P., Bonner-Weir, S., Rabelink, T.J. Preservation of β-cell function by targeting β-cell mass. Trends Pharmacol Sci 2008, 29(4): 218-27.
69. Leighton, B., Atkinson, A.M., Coope, G.J., Coghlan, M.P. Improved glycemic control after sub-acute administration of a glucokinase activator to male Zucker (fa/fa) rats. Diabetes 2007, 56(Suppl. 1): 377-OR.
70. Sörhede Winzell, M., Coghlan, M., Leighton, B., Smith, D.M., Ahrén, B. Glucokinase activation reduces glycemia and improves glucose tolerance in mice with high-fat diet-induced insulin resistance. Diabetes 2007, 56(Suppl. 1): 1482-P.
71. O'Doherty, R.M., Lehman, D.L., Télémaque-Potts, S., Newgard, C.B. Metabolic impact of glucokinase overexpression in liver. Lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 1999, 48(10): 2022-7.
72. Futamura, M., Hosaka, H., Kadotani, A. et al. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 2006, 281(49): 37668-74.
73. Nagata, Y., Sasaki, K., Hosaka, H. et al. Identification and evaluation of a novel glucokinase allosteric activator in target cells and animal model of type 2 diabetes. Diabetes 2004, 53(Suppl. 2): 587-P.
74. Eiki, J.-i., Kasuga, K., Sasaki, K. et al. Glucokinase activation directly enhances net hepatic glucose uptake during intraportal glucose infusion in normal conscious dogs. Diabetes 2006, 55(Suppl. 1): 1406-P.
75. Camacho, R.C., Qureshi, S.A., Yang, X., Eiki, J.-i., Zhang, B.B. Stimulation of insulin secretion and enhancement of insulin action, in vivo, by a small molecule glucokinase activator. Diabetes 2009, 58(Suppl. 1): 1501-P.
76. Nakamura, A., Takamoto, I., Kubota, N. et al. Impact of small molecule glucokinase activator on glucose metabolism in response to high-fat-diet in mice with β-cell specific haploinsufficiency of glucokinase gene. Diabetes 2007, 56(Suppl. 1): 529-P.
77. Nakamura, A., Terauchi, Y., Ohyama, S. et al. Impact of small-molecule glucokinase activator on glucose metabolism and β-cell mass. Endocrinology 2009, 150(3): 1147-54.
78. Nakamura, A., Ohyama, S., Kubota, J. et al. Impact of small molecule glucokinase activator on glucose metabolism, β-cell function and mass. Diabetes 2008, 57(Suppl. 1): 493-P.
79. Rhodes, C.J. Type 2 diabetes - A matter of β-cell life and death? Science 2005, 307(5708): 380-4.
80. Ohyama, S., Takano, H., Satow, A., Fukuroda, T., Iino, T., Nishimura, T., Zhang, B.B., Eiki, J.-i. A small molecule glucokinase activator lowers blood glucose in rats desensitized to sulfonylurea agents. Diabetes 2009, 58(Suppl. 1): 1537-P.
81. Del Prato, S., Pulizzi, N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metab Clin Exp 2006, 55(Suppl. 1): S20-7.
82. Kahn, S.E., Haffner, S.M., Heise, M.A. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New Engl J Med 2006, 355(23): 2427-43.
83. Futamura, M., Maruki, H., Shimazaki, H. et al. Protective effect of glucokinase activation against hydrogen peroxide-induced cell death in a model of pancreatic β-cells. Diabetes 2009, 58(Suppl. 1): 1569-P.
84. Iino, T., Tsukuhara, D., Kamata, K. et al. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thlazolyl benzamides as novel allosteric glucokinase activators. Bioorg Med Chem 2009, 17(7): 2733-43.
85. Iino, T., Hashimoto, N., Sasaki, K. et al. Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. Bioorg Med Chem 2009, 17(11): 3800-9.
86. Migoya, E.M., Miller, J., Maganti, L., Gottesdeiner, K., Wagner, J.A. The glucokinase (GK) activator MK-0599 lowers plasma glucose concentrations in healthy non-diabetic subjects. Diabetes 2009, 58(Suppl. 1): 116-OR.
87. Bertram, L.S., Black, D., Briner, P.H. et al. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2- ylacetamides: Discovery of PSN-GK1. J Med Chem 2008, 51(14): 4340-5.
88. Fyfe, M.C.T., White, J.R., Taylor, A. et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 2007, 50(6): 1277-87.
89. Castelhano, A.L., Dong, H., Fyfe, M.C.T. et al. Glucokinase-activating ureas. Bioorg Med Chem Lett 2005, 15(5): 1501-4.
90. Fyfe, M.C.T., Cawthorne, M.A., Sennitt, M.V., Printz, R.L. Antihyperglycemic effects of novel long- and short-acting glucokinase activators (PSN105 and PSN010) in diabetic animals. Diabetes 2005, 54(Suppl. 1): 522-P.
91. OSI Pharmaceuticals licenses its glucokinase activator program for the treatment of type 2 diabetes to Ell Lilly and Company. OSI Pharmaceuticals, Inc. Press Release, January 5, 2007.
92. Heuser, S., Barrett, D.G., Berg, M. et al. Synthesis of novel cyclopropylic sulfones and sulfonamides acting as glucokinase activators. Tetrahedron Lett 2006, 47(16): 2675-8.
93. Shrine, J. TransTech acquires entire GKA program in diabetes from Novo. BioWorld Today 2007, 18(36): 1-2.
94. Bödvarsdóttir, T.B., Wahl, P., Santhosh, K.C. et al. 7TP355. A glucokinase activator. Diabetes 2008, 57(Suppl. 1): 328-OR.
95. Valcarce, C., Bödvarsdóttir, T., Wahl, P., Larsen, M., Fosgerau, K., Blume, N., Selmer, J., Mjalli, A. Liver selective glucokinase activation. A new paradigm for the treatment of type 2 diabetes. Diabetologia 2008, 51(Suppl. 1): Abst 929.
96. Aicher, T., Boyd, S., Chicharelli, M. et al. Identification of glucokinase activators with euglycemic effects in normal and diabetic mouse models. Keystone Symp Diabetes Mellitus Insulin Action Resist (Jan 22-27, Breckenridge) 2008, Abst 208.
97. Aicher, T., Boyd, S., Anderson, D. et al. Discovery of ARRY-588, a novel glucokinase activator with potent glucose lowering activity in animal models of type 2 diabetes mellitus. Diabetes 2008, 57(Suppl. 1): 465-P.
98. Boyd, S.A. ARRY-588 and ARRY-403: Novel glucokinase activators with potent glucose-lowering activity in animal models of type 2 diabetes mellitus. SMI Metab Dis Conf (Sept 25, London) 2008.
99. Array BioPharma initiates clinical trial in type 2 diabetic patients. Array BioPharma Press Release, April 8, 2009.
100. McVean, M., Aicher, T.D., Boyd, S.A. et al. ARRY-403, a novel, efficacious GKA optimized for low hypoglycaemic potential in normal and diabetic rodent models. Keystone Symp Type 2 Diabetes Insulin Resist (Jan 20-25, Banff) 2009, Abst 277.
101. Aicher, T.D., Anderson, D., Boyd, S.A. et al. ARRY-403, a novel glucokinase activator with potent glucose-dependent anti-hyperglycemic activity in animal models of type 2 diabetes mellitus. Keystone Symp Type 2 Diabetes Insulin Resist (Jan 20-25, Banff) 2009, Abst 126.
102. Kim, D., Wang, L., Beconi, M. et al. (2R)-4-Oxo-4-[3-(trifluoromethyl) -5, 6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48(1): 141-51.
103. McVean, M., Aicher, T.D., Boyd, S.A., Trevillyan, J.M., Neitzel, N.A., Lee, P.A., Williams, L. Combination therapy of ARRY-403 with metformin, sitagliptin, or pioglitazone results in additive glucose lowering in female ZDF rats. Keystone Symp Type 2 Diabetes Insulin Resist (Jan 20-25, Banff) 2009, Abst 104.
104. Larsen, P.J., Wulff, E.M., Gotfredsen, C.F., Brand, C.L., Sturis, J., Vrang, N., Knudsen, L.B., Lykkegaard, K. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rots. Diabetes Obes Metab 2008, 10(4): 301-11.
105. Zelent, D., Najafi, H., Odili, S. et al. Glucokinase and glucose homeostasis: Proven concepts and new ideas. Biochem Soc Trans 2005, 33(Pt. 1): 306-10.
106. Light, P.E. The ABCs of sulfonylurea receptors, islet KATP channels and the control of insulin secretion. Can J Diabet 2002, 26(3): 223-31.
107. Donath, M.Y., Ehses, J.A., Maedler, K. et al. Mechanisms of β-cell death in type 2 diabetes. Diabetes 2005, 54(Suppl. 2): S108-13.
108. Al-Hasani, H., Tschöp, M.H., Cushman, S.W. Two birds with one stone: Novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism. Mol Interv 2003, 3(7): 367-70.
109. Roche strongly outperforms market in first quarter. Roche Press Release, April 16, 2009.